Inventiva（IVA）株式概要
臨床段階のバイオ医薬品会社であるInventiva S.A.は、フランス、米国および国際的なMASHおよびその他の疾患の治療のための経口低分子治療薬の開発に注力している。 詳細
IVA Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Inventiva S.A. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | €3.18 |
| 52週高値 | €6.20 |
| 52週安値 | €2.56 |
| ベータ | 0.88 |
| 1ヶ月の変化 | -27.51% |
| 3ヶ月変化 | -38.82% |
| 1年変化 | 16.73% |
| 3年間の変化 | -17.10% |
| 5年間の変化 | -72.39% |
| IPOからの変化 | -63.00% |
最新ニュース
ナラティブの更新 • Jun 17
IVA: Equity Raise And New Financing Will Support Upcoming MASH Milestones
Analysts have adjusted their price target on Inventiva to €15.37 from €11.40, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E, along with recent Street research such as Stifel's revised target. What's in the News for Inventiva Inventiva completed a follow on equity offering of American Depositary Shares, raising about US$120.0 million through the issuance of 27,272,727 ADSs at a price of US$4.40 per security, at a discount of US$0.264 per ADS.
ナラティブの更新 • Jun 03
IVA: 2026 MASH Phase 3 Milestones Will Drive Bullish Repricing Potential
Analysts have nudged their fair value estimate for Inventiva slightly higher to about €10.09, reflecting updated assumptions on the discount rate and future P/E following a lower price target from Stifel and a fresh bullish initiation from Truist. Analyst Commentary Recent research views on Inventiva point in different directions, with bullish analysts focusing on long term upside potential and bearish analysts placing more weight on execution risks and valuation discipline.Recent updates
ナラティブの更新 • Jun 17
IVA: Equity Raise And New Financing Will Support Upcoming MASH Milestones
Analysts have adjusted their price target on Inventiva to €15.37 from €11.40, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E, along with recent Street research such as Stifel's revised target. What's in the News for Inventiva Inventiva completed a follow on equity offering of American Depositary Shares, raising about US$120.0 million through the issuance of 27,272,727 ADSs at a price of US$4.40 per security, at a discount of US$0.264 per ADS.ナラティブの更新 • Jun 03
IVA: 2026 MASH Phase 3 Milestones Will Drive Bullish Repricing Potential
Analysts have nudged their fair value estimate for Inventiva slightly higher to about €10.09, reflecting updated assumptions on the discount rate and future P/E following a lower price target from Stifel and a fresh bullish initiation from Truist. Analyst Commentary Recent research views on Inventiva point in different directions, with bullish analysts focusing on long term upside potential and bearish analysts placing more weight on execution risks and valuation discipline.ナラティブの更新 • May 19
IVA: 2026 MASH Phase 3 Readout Will Underpin Bullish Repricing Outlook
Analysts have trimmed their fair value estimate for Inventiva slightly from about €10.00 to about €9.97, pointing to updated assumptions around profit margins and a higher future P/E that balance recent caution from one research house with a more bullish initiation from another. Analyst Commentary Bullish Takeaways Bullish analysts see the slightly higher assumed future P/E as support for the idea that investors may be willing to pay up for the stock if execution on the current pipeline stays on track.ナラティブの更新 • May 04
IVA: 2026 MASH Phase 3 Readout Will Drive Repricing Thesis
Analysts have trimmed their price target on Inventiva by €2, reflecting slightly more cautious revenue growth assumptions, expectations for stronger profit margins, and a marginally lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see the revised price target as still consistent with meaningful upside potential if Inventiva can deliver on revenue expectations and margin improvement.ナラティブの更新 • Apr 20
IVA: 2026 MASH Phase 3 Readout Will Support Repricing Thesis
Analysts now see Inventiva’s fair value holding at €10.00, with the latest price target update explained by a slightly higher discount rate, adjusted revenue growth and margin assumptions, and a lower future P/E multiple following recent initiation and target revision reports from several firms. Analyst Commentary Recent Street research on Inventiva points to a mix of optimism around the long term setup and caution around execution risk.ナラティブの更新 • Apr 06
IVA: 2026 MASH Phase 3 Readout Will Drive Repricing Narrative
The analyst price target for Inventiva has shifted from €8.98 to about €10.00, reflecting updated analyst views that balance a slightly higher discount rate with Street research highlighting lanifibranor's profile in MASH and recent supportive coverage from multiple firms. Analyst Commentary Street research around Inventiva centers on how effectively the company can turn lanifibranor's MASH profile into a de-risked late stage asset and how that potential squares with recent price target resets and rating changes.ナラティブの更新 • Mar 23
IVA: Bullish MASH Program Coverage Will Highlight Upcoming Clinical Milestone Catalysts
The analyst price target for Inventiva has been revised to €11.40. This reflects analysts' use of a slightly higher discount rate, an updated view on very large revenue growth potential, and adjusted future P/E assumptions informed by recent bullish initiations and upgrades on the stock.ナラティブの更新 • Mar 08
IVA: 2026 MASH Phase 3 Readout Expected To Drive Bullish Repricing
Analysts have increased their average price target for Inventiva to €12, up from €3, citing fresh bullish initiations and upgrades that highlight lanifibranor's differentiated profile in metabolic dysfunction-associated steatohepatitis, its inclusion among preferred small and mid cap biotech names with key upcoming catalysts, and its broader pipeline. Analyst Commentary Recent research coverage clusters around a constructive view on Inventiva, with several firms setting price targets around €12 and highlighting both the lead MASH asset and the broader pipeline as key pieces of the story.ナラティブの更新 • Feb 21
IVA: 2026 MASH Phase 3 Readout Will Support Bullish Repricing View
Analysts have raised their Inventiva fair value estimate from €7.85 to approximately €8.98, citing recent Buy and Outperform initiations that underscore confidence in lanifibranor's MASH potential and a modest increase in the assumed future P/E multiple. Analyst Commentary Recent research coverage paints a generally constructive picture for Inventiva, with several firms starting or updating views that focus on lanifibranor's potential in MASH and re-rating the shares using higher P/E assumptions and price targets.ナラティブの更新 • Feb 07
IVA: Bullish Coverage And Equity Raises Will Highlight Upcoming MASH Catalyst
The analyst price target for Inventiva has moved from $10.00 to $11.40 as analysts factor in recent bullish initiations and upgrades that highlight lanifibranor's profile in MASH and identify the company as part of a group with key upcoming catalysts and broader pipelines. Analyst Commentary Bullish analysts are clustering around a constructive view on Inventiva, pointing to recent initiations and upgrades that anchor higher valuation frameworks to the MASH opportunity and the broader pipeline.ナラティブの更新 • Jan 22
IVA: 2026 Phase 3 MASH Readout Will Drive Bullish Repricing Narrative
Narrative Update on Inventiva Analysts have raised their price targets on Inventiva to a range of about US$12 to US$13 per share, up from around US$3 in earlier research. They cite new Outperform and Buy ratings that highlight lanifibranor's pan PPAR profile in MASH and upcoming clinical catalysts as key supports for a higher valuation framework.ナラティブの更新 • Jan 08
IVA: 2026 Phase 3 MASH Readout Expected To Unlock Upside Repricing
Analysts have raised their price target on Inventiva to $12 from $3, citing growing confidence in upcoming lanifibranor data, a broader biotech re-rating, and what they view as a de-risked, best-in-class pipeline with multiple catalysts ahead. Analyst Commentary Recent Street research around Inventiva clusters around a more constructive view of its lead asset lanifibranor and the company’s late stage pipeline, which analysts link directly to their higher valuation frameworks and upgraded views on the stock.ナラティブの更新 • Dec 23
IVA: 2026 Phase 3 MASH Data Will Drive Upside Repricing
Analysts have modestly reduced their price target on Inventiva to $7.85 from $8.20 while maintaining a constructive stance based on expectations that lanifibranor could show superior fibrosis improvement in the pivotal Phase 3 NATiV3 trial, which is expected in the second half of 2026. Analyst Commentary Bullish analysts highlight that despite the modest reduction in the price target, the longer term valuation framework remains driven by the potential of lanifibranor to outperform currently approved MASH therapies on fibrosis endpoints.ナラティブの更新 • Dec 09
IVA: 2026 Phase 3 Fibrosis Data Will Drive Significant Upside Potential
Analysts have modestly raised their price target on Inventiva to $13.00, reflecting increased confidence in lanifibranor's potential for superior fibrosis improvement ahead of the pivotal Phase 3 NATiV3 data, which is expected in the second half of 2026. Analyst Commentary Recent Street research highlights a generally constructive stance on Inventiva, anchored by optimism around lanifibranor's potential differentiation in the emerging MASH treatment landscape and the value inflection expected around the Phase 3 NATiV3 readout in the second half of 2026.分析記事 • Dec 03
These Analysts Think Inventiva S.A.'s (EPA:IVA) Sales Are Under Threat
The latest analyst coverage could presage a bad day for Inventiva S.A. ( EPA:IVA ), with the analysts making...ナラティブの更新 • Nov 25
IVA: Upcoming 2026 Phase 3 Data Will Unlock Significant Upside Potential
Inventiva's analyst price target has been raised from $7.95 to $8.20 per share. This increase reflects growing optimism among analysts due to increased confidence in lanifibranor's potential Phase 3 efficacy and expanding market opportunities.ナラティブの更新 • Nov 06
IVA: Phase 3 Readout Will Drive Future Upside Amid Bullish Coverage
Analysts have maintained their fair value estimate for Inventiva at $7.95, citing continued optimism around forthcoming Phase 3 data. There is also a growing consensus on the promising outlook for lanifibranor in the MASH market.分析記事 • Oct 31
The Price Is Right For Inventiva S.A. (EPA:IVA) Even After Diving 30%
Inventiva S.A. ( EPA:IVA ) shares have retraced a considerable 30% in the last month, reversing a fair amount of their...ナラティブの更新 • Oct 23
Analysts Boost Inventiva Price Target Amid Optimism for MASH Market and Pipeline Progress
Analysts have raised their average price target for Inventiva from $9 to $13 per share, citing increased optimism for the Metabolic-Associated Steatohepatitis market as well as a larger anticipated target patient population. Analyst Commentary Bullish Takeaways Bullish analysts have increased their price targets, reflecting heightened enthusiasm for the Metabolic-Associated Steatohepatitis market and an anticipated expansion in the eligible patient population.ナラティブの更新 • Oct 09
Phase III Trials Will Advance Lanifibranor For MASH Treatment
Analysts have increased their fair value estimate for Inventiva from $6.45 to $7.95 per share. They cited greater conviction in revenue growth potential and profit margins for its lead asset in the metabolic disease market.分析記事 • Oct 08
Revenue Downgrade: Here's What Analysts Forecast For Inventiva S.A. (EPA:IVA)
The latest analyst coverage could presage a bad day for Inventiva S.A. ( EPA:IVA ), with the analysts making...分析記事 • Sep 04
Need To Know: The Consensus Just Cut Its Inventiva S.A. (EPA:IVA) Estimates For 2025
Today is shaping up negative for Inventiva S.A. ( EPA:IVA ) shareholders, with the analysts delivering a substantial...分析記事 • Aug 15
There's Reason For Concern Over Inventiva S.A.'s (EPA:IVA) Massive 27% Price Jump
The Inventiva S.A. ( EPA:IVA ) share price has done very well over the last month, posting an excellent gain of 27...
新しいナラティブ • Apr 02
Phase III Trials Will Advance Lanifibranor For MASH Treatment
Strategic focus on lanifibranor development, cutting other activities, and reducing workforce may improve net margins through operational efficiency.分析記事 • Apr 02
Need To Know: Analysts Are Much More Bullish On Inventiva S.A. (EPA:IVA)
Inventiva S.A. ( EPA:IVA ) shareholders will have a reason to smile today, with the analysts making substantial...分析記事 • Feb 27
Revenues Not Telling The Story For Inventiva S.A. (EPA:IVA) After Shares Rise 36%
Inventiva S.A. ( EPA:IVA ) shares have had a really impressive month, gaining 36% after a shaky period beforehand. But...分析記事 • Sep 27
Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely
Unfortunately for some shareholders, the Inventiva S.A. ( EPA:IVA ) share price has dived 28% in the last thirty days...分析記事 • Jun 18
More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%
Inventiva S.A. ( EPA:IVA ) shareholders that were waiting for something to happen have been dealt a blow with a 28...分析記事 • Jun 14
Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why
Key Insights Inventiva to hold its Annual General Meeting on 20th of June Total pay for CEO Frederic Cren includes...分析記事 • Mar 19
Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking
Those holding Inventiva S.A. ( EPA:IVA ) shares would be relieved that the share price has rebounded 27% in the last...分析記事 • Jan 16
Some Confidence Is Lacking In Inventiva S.A.'s (EPA:IVA) P/S
When close to half the companies in the Biotechs industry in France have price-to-sales ratios (or "P/S") below 5.8x...株主還元
| IVA | FR Biotechs | FR 市場 | |
|---|---|---|---|
| 7D | 1.3% | 1.0% | -2.0% |
| 1Y | 16.7% | 257.4% | 4.8% |
業界別リターン: IVA過去 1 年間で257.4 % の収益を上げたFrench Biotechs業界を下回りました。
リターン対市場: IVA過去 1 年間で4.8 % の収益を上げたFrench市場を上回りました。
価格変動
| IVA volatility | |
|---|---|
| IVA Average Weekly Movement | 9.1% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in FR Market | 10.7% |
| 10% least volatile stocks in FR Market | 2.7% |
安定した株価: IVAの株価は、 French市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: IVAの weekly volatility ( 9% ) は過去 1 年間安定していますが、依然としてFrenchの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2011 | 73 | Andrew Obenshain | inventivapharma.com |
Inventiva S.A.は臨床段階にあるバイオ医薬品会社で、フランス、米国、および国際的にMASHおよびその他の疾患の治療を目的とした経口低分子治療薬の開発に注力している。進行性の慢性肝疾患である代謝機能障害に伴う脂肪性肝炎の治療薬としてラニフィブラノールを開発し、第III相臨床試験を実施中である。また、細胞内にグリコサミノグリカン（GAG）として知られる大きな糖鎖が過剰に蓄積することを特徴とする希少な遺伝性疾患群であるムコ多糖症（MPS）の治療薬としてオディパルシルを開発している。また、癌やその他の疾患における初期段階のパイプラインも有している。同社は2011年に法人化され、フランスのデクスに本社を置いている。
Inventiva S.A. 基礎のまとめ
| IVA 基礎統計学 | |
|---|---|
| 時価総額 | €624.16m |
| 収益（TTM） | -€354.14m |
| 売上高(TTM) | €6.76m |
97.5x
P/Sレシオ-1.9x
PER（株価収益率IVA は割高か？
公正価値と評価分析を参照収益と収入
| IVA 損益計算書（TTM） | |
|---|---|
| 収益 | €6.76m |
| 売上原価 | €22.00k |
| 売上総利益 | €6.74m |
| その他の費用 | €360.88m |
| 収益 | -€354.14m |
直近の収益報告
Dec 31, 2025
次回決算日
Sep 25, 2026
| 一株当たり利益（EPS） | -1.70 |
| グロス・マージン | 99.67% |
| 純利益率 | -5,237.95% |
| 有利子負債／自己資本比率 | -799.8% |
IVA の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/23 11:01 |
| 終値 | 2026/06/23 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Inventiva S.A. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。22
| アナリスト | 機関 |
|---|---|
| Eliana Merle | Barclays |
| Edward Nash | Canaccord Genuity |
| Etzer Darout | Guggenheim Securities, LLC |